Relief Therapeutics, a Swiss biopharma commercializing a portfolio of drugs targeting rare diseases, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering. The company is currently listed on the SIX Swiss Exchange (RLF).
Relief Therapeutics is focused on identifying, developing, and commercializing novel, patent protected products in selected specialty, rare, and ultra-rare disease areas on a global basis. The company currently focuses on three therapeutic areas: Rare Metabolic Disorders, Rare Skin Diseases, and Rare Respiratory Diseases. Relief's diversified portfolio comprises a rare disease product that is commercialized in the EU and that it plans to launch in the US in the 4Q22, as well as a pipeline of products at various stages of development.
The Genève, Switzerland-based company was founded in 2007 and booked $5 million in sales for the 12 months ended December 31, 2021. It plans to list on the Nasdaq under the symbol RLFT. The company has not selected an underwriter yet. No pricing terms were disclosed.
